Crossmark

Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration

Crossref DOI link: https://doi.org/10.1007/s10147-018-01388-5

Published Online: 2019-01-02

Published Print: 2019-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shigeta, Keisuke

Kosaka, Takeo http://orcid.org/0000-0002-4371-4594
Hongo, Hiroshi

Yanai, Yoshinori

Matsumoto, Kazuhiro

Morita, Shinya

Mizuno, Ryuichi

Shinojima, Toshiaki

Kikuchi, Eiji

Oya, Mototsugu
License Information

Text and Data Mining valid from 2019-01-02
More Information

Article History

Received: 2 August 2018

Accepted: 24 December 2018

First Online: 2 January 2019

Change Date: 2 March 2019

Change Type: Correction

Change Details: The original article can be found online.

Compliance with ethical standards

:

: None of the authors has any conflict of interest.

Updates are available Correction dated 2019-03-02

Click to view Correction: https://doi.org/10.1007/s10147-019-01395-0